2015 American Transplant Congress
Renal Function Following Basiliximab Induction in Liver Transplant Recipients
Washington University School of Medicine, St. Louis.
Purpose: Reports of the use of antibody induction to delay the start of calcineurin inhibitor therapy postoperatively in patients with renal insufficiency at the time…2015 American Transplant Congress
Induction Therapy Improves 15-Year Graft Survival in Kidney Transplant Recipients With Acute Rejection
Transplant Institute, Henry Ford Hospital, Detroit, MI.
Background: Graft(GS) and patient survival(PS) has been shown to be superior in patients without delayed graft function (DGF) or acute rejection(AR). Induction therapy(IT) is frequently…2015 American Transplant Congress
Early Use of Anti-Lymphocyte Antibody in Kidney Transplant Recipients With Delayed Graft Function Can Produce Desirable Post-Transplant Results
Department of Transplantation Surgery, Yonsei University Health System, Seoul, Republic of Korea.
Proper management of delayed graft function (DGF) is essential for successful post-transplant result in deceased donor kidney transplantation. We compared the effect of anti-lymphocyte antibody…2015 American Transplant Congress
Optimal Induction Therapy (IT) in Pancreas After Kidney Transplantation (PAK) According to Type of Kidney (kd) Donor and Patient Risk – A Registry Analysis
1University of Arizona, Tucson, AZ; 2University of Arizona, Tucson, AZ.
Purpose: Best IT in PAK recipients (rec) according to type of kd donor (LD vs. DD) and rec risk has not been determined.Methods: Using the…2015 American Transplant Congress
Propensity Score-Weighted Analysis of Induction Therapies in Live Donor Kidney Transplantation in Modern Immunosuppression Era
1Medicine, UTSW, Dallas, TX; 2Clinical Sciences, UTSW, Dallas, TX; 3Surgery, UTSW, Dallas, TX.
Background: Induction therapy with interleukin-2 receptor antagonist (IL2-RA) is recommended as a first line agent in living donor renal transplantation (LRT). However, use of IL2-RA…2015 American Transplant Congress
Effect of Induction in Renal Transplant Recipients Aged 70 and Over
Transplantation, Montefiore Medical Center, Bronx, NY.
While there is a significant survival advantage to transplanting patients 70 years of age and older versus staying on dialysis, it is unclear whether sensitized…2015 American Transplant Congress
Kidney Patients at High Immunological Risk Can Be Safely Transplanted With a Novel Induction Regimen Using Anti-Thymocyte Globulin (Rabbit) (rATG) Plus Basiliximab
Purpose: We report the outcomes from our single center experience with the novel induction regimen using rATG (3 mg/kg) in divided doses given on operative…2015 American Transplant Congress
Alemtuzumab Induction Has Been Safe in the United Kingdom and Achieves Long-Term Steroid Avoidance in More Than 80% of Low Risk Renal Transplant Recipients
Introduction: The use of alemtuzumab as an induction agent for renal transplantation is increasing in the UK. There is some evidence to suggest that this…2015 American Transplant Congress
Delayed Graft Function in Patients Receiving Alemtuzumab Induction Therapy
1The University of Toledo Medical Center, Toledo, OH; 2The Alliance for Paired Donation, Maumee, OH.
Alemtuzumab (Campath 1-H) is a humanized monoclonal antibody directed at the CD52 glycoprotein that is becoming more prevalent as a choice for induction. Delayed graft…2015 American Transplant Congress
Alemtuzumab Induction Is Associated With Higher Risk of Polyomavirrus Associated Nephropathy (PVAN) in Kidney Transplant Recipients
1Transplant, Mayo Clinic, Jacksonville, FL; 2Pharmacy, Mayo Clinic, Jacksonville, FL.
Incidence of PVAN on protocol kidney biopsies with alemtuzumab induction is unknown.Methods:The 1-year risk of PVAN was retrospectively compared between 200 consecutive primary kidney recipients…
American Transplant Congress abstracts